Cargando…
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects
Although phase I to III trials represent the standard for introducing new drugs to clinical therapy, there has been increasing demand for translational research in oncology over the past decade. Thus, for most novel therapies such as 'targeted agents', a critical aspect for drug developmen...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614848/ https://www.ncbi.nlm.nih.gov/pubmed/19128436 http://dx.doi.org/10.1186/bcr2182 |